The Tremor drugs in development market research report provides comprehensive information on the therapeutics under development for Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tremor. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Tremor - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tremor and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Tremor by 17 companies/universities/institutes. The top development phase for Tremor is phase ii with nine drugs in that stage. The Tremor pipeline has 20 drugs in development by companies and one by universities/ institutes. Some of the companies in the Tremor pipeline products market are: Jazz Pharmaceuticals, Neurocrine Biosciences and AfaSci.

The key targets in the Tremor pipeline products market include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR), Voltage Dependent T Type Calcium Channel, and Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25).

The key mechanisms of action in the Tremor pipeline product include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR) Agonist with three drugs in Phase III. The Tremor pipeline products include nine routes of administration with the top ROA being Oral and two key molecule types in the Tremor pipeline products market including Small Molecule, and Protein.

Tremor overview

Tremor is a neurological condition characterized by involuntary shaking or trembling movements in various body parts, primarily the hands but potentially affecting the arms, legs, head, vocal cords, and trunk, as a result of uncontrollable muscle contractions. Its impact varies, causing intermittent or constant challenges in daily tasks like writing, typing, eating, and dressing. While not life-threatening, severe cases can lead to disabilities. Essential tremor, Parkinsonian tremor associated with Parkinson’s disease, and dystonic tremor are common types. The cause often stems from deep brain issues, with some types being hereditary. Various factors, including neurologic disorders, certain medications, alcohol use disorder, poisoning, hyperthyroidism, and anxiety, may contribute. Symptoms range from rhythmic shaking to difficulty writing. Diagnosis involves a neurological exam assessing balance, speech, and muscle stiffness. Treatment options encompass medications, Botox injections, surgery (such as deep brain stimulation), and therapy to manage tremor and its daily implications.

For a complete picture of Tremor’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.